Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration [4]

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4814-4815

  Li, J ^a   Rayner, C R ^a   Nation, R L ^a   Deans, R ^b   Boots, R ^b   Widdecombe, N ^b   Douglas, A ^b   Lipman, J ^b  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; MEROPENEM; TOBRAMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; CASE REPORT; CRITICAL ILLNESS; DIALYSATE LEVEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; GRAM NEGATIVE INFECTION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTESTINE PERFORATION; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS;

COLISTIN; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HUMANS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA;

EID: 27644585168     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4814-4815.2005     Document Type: Letter

References (14)

1. Berlana, D., J. M. Llop, E. Fort, M. B. Badia, and R. Jodar. 2005. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am. J. Health Syst. Pharm. 62:39-47.
2. DelDot, M. E., J. Lipman, and S. E. Tett. 2004. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br. J. Clin. Pharmacol. 58:259-268.
3. Goodwin, N. J., and E. A. Friedman. 1968. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann. Intern. Med. 68:984-994.
4. Li, J., R. W. Milne, R. L. Nation, J. D. Turnidge, K. Coulthard, and D. W. Johnson. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B 761:167-175.
5. Li, J., R. W. Milne, R. L. Nation, J. D. Turnidge, K. Coulthard, and J. Valentine. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 46:3304-3307.
6. Li, J., R. W. Milne, R. L. Nation, J. D. Turnidge, T. C. Smeaton, and K. Coulthard. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840.
7. Li, J., R. L. Nation, R. W. Milne, J. D. Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25.
8. Li, J., J. Turnidge, R. Milne, R. L. Nation, and K. Coulthard. 2001. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:781-785.
9. Linden, P., S. Kusne, K. Coley, P. Fontes, D. Kramer, and D. Paterson. 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37:E154-E60.
10. Markou, N., H. Apostolakos, C. Koumoudiou, M. Athanasiou, A. Koutsoukou, I. Alamanos, and L. Gregorakos. 2003. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit. Care 7:R78-R83.
11. Michalopoulos, A., S. Kasiakou, E. Rosmarakis, and M. Falagas. 2005. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand. J. Infect. Dis. 37:142-145.
12. Monarch Pharmaceuticals. 2000. Coly-Mycin M Parenteral. Package insert. Monarch Pharmaceuticals, Bristol, Tenn.
13. National Committee for Clinical Laboratory Standards. 1992. Methods for determining bactericidal activity of antimicrobial agents; tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
14. Pfizer. 2003. Coly-Mycin M Parenteral. Package insert. Pfizer Australia Pty. Ltd., West Ryde, NSW, Australia.